MX381041B - Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. - Google Patents

Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.

Info

Publication number
MX381041B
MX381041B MX2019015431A MX2019015431A MX381041B MX 381041 B MX381041 B MX 381041B MX 2019015431 A MX2019015431 A MX 2019015431A MX 2019015431 A MX2019015431 A MX 2019015431A MX 381041 B MX381041 B MX 381041B
Authority
MX
Mexico
Prior art keywords
coumarin
cyclic compound
mek inhibitor
type cyclic
compounds
Prior art date
Application number
MX2019015431A
Other languages
English (en)
Other versions
MX2019015431A (es
Inventor
Chengde Wu
Jian Li
Qinghua Mao
Shuhui Chen
Yong Huang
Zhen Gong
Original Assignee
Cstone Pharmaceuticals
Cstone Pharmaceuticals Shanghai Co Ltd
Cstone Pharmaceuticals Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceuticals, Cstone Pharmaceuticals Shanghai Co Ltd, Cstone Pharmaceuticals Suzhou Co Ltd filed Critical Cstone Pharmaceuticals
Publication of MX2019015431A publication Critical patent/MX2019015431A/es
Publication of MX381041B publication Critical patent/MX381041B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen una clase de compuestos cíclicos tipo cumarina como inhibidores de MEK y composiciones farmacéuticas que comprenden los compuestos, y el uso de los mismos en la preparación de un fármaco para tratar enfermedades relacionadas con MEK. Se describen particularmente compuestos como se muestra en la fórmula (I) y sus sales farmacéuticamente aceptables o tautómeros de estos.
MX2019015431A 2017-06-23 2018-06-22 Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. MX381041B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710488401 2017-06-23
CN201810596587 2018-06-11
PCT/CN2018/092457 WO2018233696A1 (zh) 2017-06-23 2018-06-22 作为mek抑制剂的类香豆素环类化合物及其应用

Publications (2)

Publication Number Publication Date
MX2019015431A MX2019015431A (es) 2021-03-30
MX381041B true MX381041B (es) 2025-03-12

Family

ID=64735508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015431A MX381041B (es) 2017-06-23 2018-06-22 Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.

Country Status (15)

Country Link
US (1) US11021486B2 (es)
EP (1) EP3643308B1 (es)
JP (1) JP6774578B2 (es)
KR (1) KR102580179B1 (es)
CN (1) CN111201225B (es)
AU (1) AU2018289864B2 (es)
CA (1) CA3067941C (es)
ES (1) ES2876293T3 (es)
IL (1) IL271550B (es)
MX (1) MX381041B (es)
RU (1) RU2742234C1 (es)
SA (1) SA519410865B1 (es)
SG (1) SG11201912997TA (es)
TW (1) TWI801394B (es)
WO (1) WO2018233696A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112912380B (zh) * 2018-12-21 2023-08-11 基石药业（苏州）有限公司 一种mek抑制剂的晶型、无定形及其应用
LV15600A (lv) * 2020-05-18 2021-11-20 Latvijas Organiskās Sintēzes Institūts Kurkumīna dihidropiridonu atvasinājumi ar pretvēža aktivitāti
KR20230172548A (ko) * 2021-04-16 2023-12-22 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
CN116036080B (zh) * 2023-04-03 2023-06-06 江西省林业科学院 吡喃并吡啶酮类化合物在制备治疗肝癌药物中的应用
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201475B1 (pl) * 1998-09-29 2009-04-30 Wyeth Corp Podstawione 3-cyjanochinoliny jako inhibitory białkowych kinaz tyrozynowych
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
WO2008127274A2 (en) 2006-09-22 2008-10-23 Ptc Therapeutics, Inc. Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
EP2307364B1 (en) 2008-07-01 2013-06-19 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
EP2714039A1 (en) 2011-05-23 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
CN102964326B (zh) * 2012-11-06 2015-11-18 北京大学 具有mek抑制功能的化合物及其制备方法与应用
CN106905316B (zh) 2013-04-18 2021-06-01 上海复尚慧创医药研究有限公司 蛋白激酶抑制剂
US9914703B2 (en) 2013-10-25 2018-03-13 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof
CN105153142B (zh) * 2014-06-03 2018-01-19 复旦大学 香豆素母核的呋咱衍生物及抗肿瘤活性
CN105287509A (zh) * 2014-08-01 2016-02-03 陶建臣 一种mek激酶抑制剂
JP2016155776A (ja) 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
CN106810558A (zh) 2015-11-27 2017-06-09 成都贝斯凯瑞生物科技有限公司 成纤维细胞生长因子受体选择性抑制剂及其应用

Also Published As

Publication number Publication date
JP2020524705A (ja) 2020-08-20
SG11201912997TA (en) 2020-01-30
CN111201225B (zh) 2021-11-05
CA3067941A1 (en) 2018-12-27
JP6774578B2 (ja) 2020-10-28
AU2018289864A1 (en) 2020-02-06
US11021486B2 (en) 2021-06-01
RU2742234C1 (ru) 2021-02-03
KR20200015787A (ko) 2020-02-12
CA3067941C (en) 2020-08-18
ES2876293T3 (es) 2021-11-12
BR112019027292A2 (pt) 2020-07-21
MX2019015431A (es) 2021-03-30
SA519410865B1 (ar) 2022-07-25
IL271550B (en) 2021-03-25
KR102580179B1 (ko) 2023-09-18
TW201904973A (zh) 2019-02-01
AU2018289864B2 (en) 2022-03-31
TWI801394B (zh) 2023-05-11
US20200148695A1 (en) 2020-05-14
IL271550A (en) 2020-02-27
EP3643308A4 (en) 2020-04-29
EP3643308B1 (en) 2021-05-19
EP3643308A1 (en) 2020-04-29
WO2018233696A1 (zh) 2018-12-27
CN111201225A (zh) 2020-05-26

Similar Documents

Publication Publication Date Title
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
EA201792116A1 (ru) Ингибитор янус-киназы
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112017017135A2 (pt) inibidores de tgf-beta
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
BR112016016844A2 (pt) Compostos heterocíclicos
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX390747B (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MX380276B (es) Inhibidor jak.
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
JOP20190174A1 (ar) مثبطات jak1 انتقائية
BR112014008495B8 (pt) Composto inibidor da proteína quinase, composição farmacêutica compreendendo-o e uso do mesmo para a fabricação de um medicamento para o tratamento de câncer
MX375484B (es) Derivados de azabencimidazol como inhibidores de pi3k beta
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
MX2015017512A (es) Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط